Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction

Interleukin 6 receptor (IL6R) inhibitor, tocilizumab, has been effectively used in the treatment of cytokine release syndrome in patients receiving chimeric antigen receptor T-cell therapy. Here we present a patient with chronic myelomonocytic leukemia (CMML) who developed a steroid refractory, post...

Descripción completa

Detalles Bibliográficos
Autores principales: Melody, Megan, Butts, Emily, Menke, David, Landolfo, Kevin, Oken, Keith, Sher, Taimur, Khurana, Sharad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672312/
https://www.ncbi.nlm.nih.gov/pubmed/33240789
http://dx.doi.org/10.1016/j.lrr.2020.100228
_version_ 1783611106821931008
author Melody, Megan
Butts, Emily
Menke, David
Landolfo, Kevin
Oken, Keith
Sher, Taimur
Khurana, Sharad
author_facet Melody, Megan
Butts, Emily
Menke, David
Landolfo, Kevin
Oken, Keith
Sher, Taimur
Khurana, Sharad
author_sort Melody, Megan
collection PubMed
description Interleukin 6 receptor (IL6R) inhibitor, tocilizumab, has been effectively used in the treatment of cytokine release syndrome in patients receiving chimeric antigen receptor T-cell therapy. Here we present a patient with chronic myelomonocytic leukemia (CMML) who developed a steroid refractory, post-operative myelomonocytic leukemoid reaction (PO-MMLR), effectively treated with tocilizumab. Although, further studies are needed to validate the effectiveness of tocilizumab in management of PO-MMLR, this case serves to provide a new management approach in treatment of this rare but lethal syndrome with no standardized treatment options.
format Online
Article
Text
id pubmed-7672312
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-76723122020-11-24 Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction Melody, Megan Butts, Emily Menke, David Landolfo, Kevin Oken, Keith Sher, Taimur Khurana, Sharad Leuk Res Rep Article Interleukin 6 receptor (IL6R) inhibitor, tocilizumab, has been effectively used in the treatment of cytokine release syndrome in patients receiving chimeric antigen receptor T-cell therapy. Here we present a patient with chronic myelomonocytic leukemia (CMML) who developed a steroid refractory, post-operative myelomonocytic leukemoid reaction (PO-MMLR), effectively treated with tocilizumab. Although, further studies are needed to validate the effectiveness of tocilizumab in management of PO-MMLR, this case serves to provide a new management approach in treatment of this rare but lethal syndrome with no standardized treatment options. Elsevier 2020-11-04 /pmc/articles/PMC7672312/ /pubmed/33240789 http://dx.doi.org/10.1016/j.lrr.2020.100228 Text en © 2020 Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Melody, Megan
Butts, Emily
Menke, David
Landolfo, Kevin
Oken, Keith
Sher, Taimur
Khurana, Sharad
Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction
title Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction
title_full Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction
title_fullStr Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction
title_full_unstemmed Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction
title_short Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction
title_sort use of tocilizumab in management of post-operative myelomonocytic leukemoid reaction
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672312/
https://www.ncbi.nlm.nih.gov/pubmed/33240789
http://dx.doi.org/10.1016/j.lrr.2020.100228
work_keys_str_mv AT melodymegan useoftocilizumabinmanagementofpostoperativemyelomonocyticleukemoidreaction
AT buttsemily useoftocilizumabinmanagementofpostoperativemyelomonocyticleukemoidreaction
AT menkedavid useoftocilizumabinmanagementofpostoperativemyelomonocyticleukemoidreaction
AT landolfokevin useoftocilizumabinmanagementofpostoperativemyelomonocyticleukemoidreaction
AT okenkeith useoftocilizumabinmanagementofpostoperativemyelomonocyticleukemoidreaction
AT shertaimur useoftocilizumabinmanagementofpostoperativemyelomonocyticleukemoidreaction
AT khuranasharad useoftocilizumabinmanagementofpostoperativemyelomonocyticleukemoidreaction

Ejemplares similares